Performance Review Board Membership, 51594 [2019-21061]
Download as PDF
<![CDATA[
51594
Federal Register / Vol. 84, No. 189 / Monday, September 30, 2019 / Notices
The State of Washington has agreed to
pay the state’s pro rata share of the
anticipated overhead costs and costs of
actual validation (including complaint
investigation surveys). A final
reconciliation for all laboratories and all
expenses will be made. We will
reimburse the state for any overpayment
or bill it for any balance.
II. Approval
In light of the foregoing, we grant
approval of the State of Washington’s
laboratory licensure program under
subpart E. All laboratories located in
and licensed by the State of Washington
under the Medical Test Site law,
Chapter 70.42 of the Revised Code of
Washington, are CLIA-exempt for all
specialties and subspecialties until
October 2, 2023.
III. Collection of Information
Requirements
This document does not impose
information collection requirements,
that is, reporting, recordkeeping or
third-party disclosure requirements.
Consequently, there is no need for
review by the Office of Management and
Budget under the authority of the
Paperwork Reduction Act of 1995 (44
U.S.C. 3501 et seq.).
Dated: September 12, 2019.
Seema Verma,
Administrator, Centers for Medicare &
Medicaid Services.
rating. In addition, the PRB will review
and recommend executive performance
bonuses and pay increases.
5 U.S.C. 4314(c)(4) requires the
appointment of board members to be
published in the Federal Register. The
following persons comprise a standing
roster to serve as members of the SES
PRB for the Centers for Medicare &
Medicaid Services:
Jennifer Main, Chief Operating Officer
(serves as the Chair)
Kimberly Brandt, Principal Deputy
Administrator for Policy and
Operations
Scott Giberson, Acting Director, Office
of Human Capital
Nancy O’Connor, Acting Consortium
Administrator, Consortium for
Medicare Health Plans Operations
Randy Pate, Deputy Administrator and
Director, Center for Consumer
Information and Insurance Oversight
Elizabeth Richter, Deputy Center
Director, Center for Medicare
Arrah Tabe-Bedward, Deputy Director,
Center for Medicare and Medicaid
Innovation
Jeffrey, Deputy Director for Operations,
Center for Consumer Information and
Insurance Oversight
Dated: September 5, 2019.
Jennifer Main,
Chief Operating Officer.
[FR Doc. 2019–21061 Filed 9–27–19; 8:45 am]
BILLING CODE 4120–01–P
[FR Doc. 2019–21062 Filed 9–27–19; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2019–D–3361]
Centers for Medicare & Medicaid
Services
Eligibility Criteria for Expanded
Conditional Approval of New Animal
Drugs; Draft Guidance for Industry;
Availability
Performance Review Board
Membership
Centers for Medicare &
Medicaid Services, HHS.
ACTION: Notice of Performance Review
Board Membership.
AGENCY:
khammond on DSKJM1Z7X2PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Kathy Vaughn, 410–786–1050 or
katherine.vaughn@cms.hhs.gov.
5 U.S.C. 4314(c)(1) through (5)
requires each agency to establish, in
accordance with regulations prescribed
by the Office of Personnel Management,
one or more Senior Executive Service
(SES) Performance Review Boards.
The PRB shall review and evaluate
the initial summary rating of a senior
executive’s performance, the executive’s
response, and the higher-level official’s
comments on the initial summary
VerDate Sep<11>2014
19:16 Sep 27, 2019
Jkt 247001
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a draft
guidance for industry (GFI) #261
entitled ‘‘Eligibility Criteria for
Expanded Conditional Approval of New
Animal Drugs.’’ This draft guidance is
intended for persons interested in
pursuing conditional approval of new
animal drugs for certain major uses in
major species. Eligibility for conditional
approval has been expanded beyond
minor uses in major species and minor
species to include certain major uses.
The Center for Veterinary Medicine
SUMMARY:
PO 00000
Frm 00087
Fmt 4703
Sfmt 4703
(CVM) refers to the process for
conditionally approving new animal
drugs that are not minor use and minor
species (MUMS) drugs as ‘‘expanded
conditional approval.’’ The purpose of
expanded conditional approval is to
incentivize development of new animal
drugs for serious or life-threatening
conditions or unmet animal or human
health needs under circumstances
where a demonstration of effectiveness
would require a complex or particularly
difficult study or studies. This draft
guidance defines certain terms, clarifies
the eligibility criteria for expanded
conditional approval, and describes the
criteria CVM intends to consider when
determining expanded conditional
approval eligibility.
DATES: Submit either electronic or
written comments on the draft guidance
by January 28, 2020 to ensure that the
Agency considers your comment on this
draft guidance before it begins work on
the final version of the guidance.
ADDRESSES: You may submit comments
on any guidance at any time as follows:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
E:\FR\FM\30SEN1.SGM
30SEN1
]]>Agencies
[Federal Register Volume 84, Number 189 (Monday, September 30, 2019)]
[Notices]
[Page 51594]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-21061]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
Performance Review Board Membership
AGENCY: Centers for Medicare & Medicaid Services, HHS.
ACTION: Notice of Performance Review Board Membership.
-----------------------------------------------------------------------
FOR FURTHER INFORMATION CONTACT: Kathy Vaughn, 410-786-1050 or
[email protected].
5 U.S.C. 4314(c)(1) through (5) requires each agency to establish,
in accordance with regulations prescribed by the Office of Personnel
Management, one or more Senior Executive Service (SES) Performance
Review Boards.
The PRB shall review and evaluate the initial summary rating of a
senior executive's performance, the executive's response, and the
higher-level official's comments on the initial summary rating. In
addition, the PRB will review and recommend executive performance
bonuses and pay increases.
5 U.S.C. 4314(c)(4) requires the appointment of board members to be
published in the Federal Register. The following persons comprise a
standing roster to serve as members of the SES PRB for the Centers for
Medicare & Medicaid Services:
Jennifer Main, Chief Operating Officer (serves as the Chair)
Kimberly Brandt, Principal Deputy Administrator for Policy and
Operations
Scott Giberson, Acting Director, Office of Human Capital
Nancy O'Connor, Acting Consortium Administrator, Consortium for
Medicare Health Plans Operations
Randy Pate, Deputy Administrator and Director, Center for Consumer
Information and Insurance Oversight
Elizabeth Richter, Deputy Center Director, Center for Medicare
Arrah Tabe-Bedward, Deputy Director, Center for Medicare and Medicaid
Innovation
Jeffrey, Deputy Director for Operations, Center for Consumer
Information and Insurance Oversight
Dated: September 5, 2019.
Jennifer Main,
Chief Operating Officer.
[FR Doc. 2019-21061 Filed 9-27-19; 8:45 am]
BILLING CODE 4120-01-P
